Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS.

Rutherford BR, Bailey VS, Schneier FR, Pott E, Brown PJ, Roose SP.

Depress Anxiety. 2015 Dec;32(12):944-57. doi: 10.1002/da.22433. Epub 2015 Oct 5.

2.

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University, Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR.

BMC Psychiatry. 2014;14 Suppl 1:S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. Review.

3.

Optimal treatment of social phobia: systematic review and meta-analysis.

Canton J, Scott KM, Glue P.

Neuropsychiatr Dis Treat. 2012;8:203-15. doi: 10.2147/NDT.S23317. Epub 2012 May 3.

4.

Current management of obsessive and phobic states.

Goljevscek S, Carvalho LA.

Neuropsychiatr Dis Treat. 2011;7:599-610. doi: 10.2147/NDT.S17032. Epub 2011 Sep 30.

5.

Fluvoxamine in the treatment of anxiety disorders.

Irons J.

Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99.

6.

Efficacy and tolerability of second-generation antidepressants in social anxiety disorder.

Hansen RA, Gaynes BN, Gartlehner G, Moore CG, Tiwari R, Lohr KN.

Int Clin Psychopharmacol. 2008 May;23(3):170-9. doi: 10.1097/YIC.0b013e3282f4224a. Review.

Supplemental Content

Support Center